Switch theme
Sign up to access all valuation multiples
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
2019
51
Last FY Revenue n/a
Last FY EBITDA -$56.2M
$96.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Tectonic Therapeutic achieved revenue of n/a and an EBITDA of -$56.2M.
Tectonic Therapeutic expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tectonic Therapeutic valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$56.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$67.3M | XXX | -$58.0M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$64.7M | XXX | -$58.0M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Tectonic Therapeutic's stock price is $21.
Tectonic Therapeutic has current market cap of $400M, and EV of $96.4M.
See Tectonic Therapeutic trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $96.4M | $400M | XXX | XXX | XXX | XXX | $-5.70 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Tectonic Therapeutic has market cap of $400M and EV of $96.4M.
Tectonic Therapeutic's trades at n/a EV/Revenue multiple, and -1.7x EV/EBITDA.
Equity research analysts estimate Tectonic Therapeutic's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tectonic Therapeutic has a P/E ratio of -6.2x.
See valuation multiples for Tectonic Therapeutic and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $400M | XXX | $400M | XXX | XXX | XXX |
| EV (current) | $96.4M | XXX | $96.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.7x | XXX | XXX | XXX |
| EV/EBIT | -1.4x | XXX | -1.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.2x | XXX | -6.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTectonic Therapeutic's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.1M for the same period.
Tectonic Therapeutic's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tectonic Therapeutic's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Tectonic Therapeutic and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tectonic Therapeutic acquired XXX companies to date.
Last acquisition by Tectonic Therapeutic was XXXXXXXX, XXXXX XXXXX XXXXXX . Tectonic Therapeutic acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Tectonic Therapeutic founded? | Tectonic Therapeutic was founded in 2019. |
| Where is Tectonic Therapeutic headquartered? | Tectonic Therapeutic is headquartered in United States of America. |
| How many employees does Tectonic Therapeutic have? | As of today, Tectonic Therapeutic has 51 employees. |
| Who is the CEO of Tectonic Therapeutic? | Tectonic Therapeutic's CEO is Dr. Alise S. Reicin, M.D.. |
| Is Tectonic Therapeutic publicy listed? | Yes, Tectonic Therapeutic is a public company listed on NAS. |
| What is the stock symbol of Tectonic Therapeutic? | Tectonic Therapeutic trades under TECX ticker. |
| When did Tectonic Therapeutic go public? | Tectonic Therapeutic went public in 2024. |
| Who are competitors of Tectonic Therapeutic? | Similar companies to Tectonic Therapeutic include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Tectonic Therapeutic? | Tectonic Therapeutic's current market cap is $400M |
| Is Tectonic Therapeutic profitable? | Yes, Tectonic Therapeutic is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
